GB2294267B
(en)
|
1993-06-03 |
1996-11-20 |
Therapeutic Antibodies Inc |
Anti-TNFalpha Fab fragments derived from polyclonal IgG antibodies
|
GB9501683D0
(en)
|
1995-01-27 |
1995-03-15 |
Glaxo Group Ltd |
Substances and their uses
|
US5646036A
(en)
*
|
1995-06-02 |
1997-07-08 |
Genentech, Inc. |
Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
|
US5686292A
(en)
|
1995-06-02 |
1997-11-11 |
Genentech, Inc. |
Hepatocyte growth factor receptor antagonist antibodies and uses thereof
|
US6214344B1
(en)
|
1995-06-02 |
2001-04-10 |
Genetech, Inc. |
Hepatocyte growth factor receptor antagonists and uses thereof
|
GB9517538D0
(en)
*
|
1995-08-26 |
1995-10-25 |
Therapeutic Antibodies Inc |
Production and therapeutic combinations, of antibodies
|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
US6998116B1
(en)
|
1996-01-09 |
2006-02-14 |
Genentech, Inc. |
Apo-2 ligand
|
US6030945A
(en)
*
|
1996-01-09 |
2000-02-29 |
Genentech, Inc. |
Apo-2 ligand
|
RU2270030C2
(ru)
|
1996-02-09 |
2006-02-20 |
Абботт Байотекнолоджи эЛтиди. |
СПОСОБ ИНГИБИРОВАНИЯ АКТИВНОСТИ ЧЕЛОВЕЧЕСКОГО TNFα (ВАРИАНТЫ), ПРИМЕНЕНИЕ ВЫДЕЛЕННОГО АНТИТЕЛА ЧЕЛОВЕКА ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩЕГО ФРАГМЕНТА В КАЧЕСТВЕ КОМПОНЕНТА ДЛЯ ПРОИЗВОДСТВА ЛЕКАРСТВЕННОГО СРЕДСТВА (ВАРИАНТЫ) И ВЫДЕЛЕННОЕ ЧЕЛОВЕЧЕСКОЕ АНТИТЕЛО ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ
|
CA2249206A1
(en)
|
1996-04-01 |
1997-10-09 |
Genentech, Inc. |
Apo-2li and apo-3 apoptosis polypeptides
|
JP2000515735A
(ja)
*
|
1996-07-03 |
2000-11-28 |
ジェネンテック インコーポレーテッド |
肝細胞成長因子レセプターアゴニスト
|
US6462176B1
(en)
|
1996-09-23 |
2002-10-08 |
Genentech, Inc. |
Apo-3 polypeptide
|
US6136958A
(en)
*
|
1996-09-30 |
2000-10-24 |
Genentech, Inc. |
Antibodies to vertebrate smoothened proteins
|
US5990281A
(en)
|
1996-09-30 |
1999-11-23 |
Genentech, Inc. |
Vertebrate smoothened proteins
|
US6342369B1
(en)
|
1997-05-15 |
2002-01-29 |
Genentech, Inc. |
Apo-2-receptor
|
AU739350B2
(en)
|
1997-06-05 |
2001-10-11 |
University Of Texas System, The |
APAF-1, the CED-4 human homolog, an activator of caspase-3
|
JP2002508663A
(ja)
|
1997-06-18 |
2002-03-19 |
ジェネンテク,インコーポレイテッド |
Apo−2DcR
|
WO1999036535A1
(en)
|
1998-01-15 |
1999-07-22 |
Genentech, Inc. |
Apo-2 ligand
|
PT1086138E
(pt)
|
1998-06-12 |
2010-01-04 |
Genentech Inc |
Anticorpos monoclonais, anticorpos de reacção cruzada e método para produzir os mesmos
|
US7192698B1
(en)
|
1999-08-17 |
2007-03-20 |
Purdue Research Foundation |
EphA2 as a diagnostic target for metastatic cancer
|
US6927203B1
(en)
|
1999-08-17 |
2005-08-09 |
Purdue Research Foundation |
Treatment of metastatic disease
|
ATE415978T1
(de)
|
2000-07-27 |
2008-12-15 |
Genentech Inc |
Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
|
US7101976B1
(en)
|
2000-09-12 |
2006-09-05 |
Purdue Research Foundation |
EphA2 monoclonal antibodies and methods of making and using same
|
EP2336166A1
(en)
|
2000-10-12 |
2011-06-22 |
University Of Rochester |
Compositions that inhibit proliferation of cancer cells
|
US6709655B2
(en)
|
2001-02-28 |
2004-03-23 |
Instituto Bioclon, S.A. De C.V. |
Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
|
CA2868614A1
(en)
|
2001-06-08 |
2002-12-08 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
US20050069549A1
(en)
|
2002-01-14 |
2005-03-31 |
William Herman |
Targeted ligands
|
JP2005532263A
(ja)
|
2002-02-06 |
2005-10-27 |
ヴァイコー テクノロジーズ, インコーポレイテッド |
抗梗塞分子
|
EP1490085A2
(en)
|
2002-03-25 |
2004-12-29 |
Uab Research Foundation |
Fc receptor homolog, reagents, and uses thereof
|
JP4689268B2
(ja)
|
2002-06-14 |
2011-05-25 |
ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
Il−13およびnk−t細胞に関する、結腸炎を処置および予防する方法
|
AU2003257181A1
(en)
|
2002-08-05 |
2004-02-23 |
University Of Rochester |
Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
US7597936B2
(en)
|
2002-11-26 |
2009-10-06 |
University Of Utah Research Foundation |
Method of producing a pigmented composite microporous material
|
WO2004048936A2
(en)
|
2002-11-26 |
2004-06-10 |
University Of Utah Research Foundation |
Microporous materials, methods, and articles for localizing and quantifying analytes
|
AU2003298816C1
(en)
*
|
2002-12-02 |
2010-12-16 |
Amgen Fremont, Inc. |
Antibodies directed to Tumor Necrosis Factor and uses thereof
|
US7335759B2
(en)
*
|
2002-12-02 |
2008-02-26 |
Universidad Nacional Autónoma de Méxica (UNAM) |
Recombinant immunogens for the generation of antivenoms to the venom of scorpions of the genus Centruroides
|
US7141015B2
(en)
*
|
2003-05-09 |
2006-11-28 |
Bernard Joseph Ruane |
Expandable and pivotally adjustable surgical retractor
|
MXPA06000965A
(es)
*
|
2003-07-25 |
2007-05-04 |
Silanes Sa De Cv Lab |
Administracion de fragmentos f(ab??)2 de anticuerpos anti-citocinas.
|
FR2859725B1
(fr)
*
|
2003-09-16 |
2006-03-10 |
Neovacs |
Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
|
WO2005069969A2
(en)
|
2004-01-21 |
2005-08-04 |
University Of Utah Research Foundation |
Mutant sodium channel nav1.7 and methods related thereto
|
AU2005229457B2
(en)
|
2004-03-30 |
2010-11-25 |
Glaxo Group Limited |
Immunoglobulins
|
TWI439284B
(zh)
|
2004-04-09 |
2014-06-01 |
Abbvie Biotechnology Ltd |
用於治療TNFα相關失調症之多重可變劑量療法
|
TWI307630B
(en)
|
2004-07-01 |
2009-03-21 |
Glaxo Group Ltd |
Immunoglobulins
|
SI1773885T1
(sl)
|
2004-08-05 |
2010-08-31 |
Genentech Inc |
Humanizirani anti-CMET antagonisti
|
US8029783B2
(en)
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
MX2007012687A
(es)
|
2005-04-15 |
2008-03-14 |
Genentech Inc |
Variantes de cadena beta de hgf.
|
US7381802B2
(en)
*
|
2005-04-15 |
2008-06-03 |
Universidad Nacional Autónoma De México (UNAM) |
Human antibodies that specifically recognize the toxin Cn2 from Centruroides noxius scorpion venom
|
NZ591701A
(en)
|
2005-05-16 |
2012-11-30 |
Abbott Biotech Ltd |
Use of tnf inhibitor for treatment of erosive polyarthritis
|
ES2431315T3
(es)
|
2005-05-19 |
2013-11-26 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Epítopos funcionales del antígeno PsaA de Streptococcus pneumoniae y usos de los mismos
|
EP1806365A1
(en)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
|
AU2007223427A1
(en)
|
2006-03-01 |
2007-09-13 |
University Of Utah Research Foundation |
Methods and compositions related to cyclic peptide synthesis
|
US8470965B2
(en)
|
2006-03-01 |
2013-06-25 |
University Of Utah Research Foundation |
Methods and compositions related to cyclic peptide synthesis
|
NZ611859A
(en)
|
2006-04-05 |
2014-12-24 |
Abbvie Biotechnology Ltd |
Antibody purification
|
US9605064B2
(en)
|
2006-04-10 |
2017-03-28 |
Abbvie Biotechnology Ltd |
Methods and compositions for treatment of skin disorders
|
US9624295B2
(en)
|
2006-04-10 |
2017-04-18 |
Abbvie Biotechnology Ltd. |
Uses and compositions for treatment of psoriatic arthritis
|
WO2007120656A2
(en)
|
2006-04-10 |
2007-10-25 |
Abbott Biotechnology Ltd. |
Uses and compositions for treatment of rheumatoid arthritis
|
WO2008005429A2
(en)
|
2006-07-03 |
2008-01-10 |
Charles David Adair |
Composition for modulating the expression of cell adhesion molecules
|
WO2008136852A2
(en)
|
2006-11-01 |
2008-11-13 |
University Of Rochester |
Methods and compositions related to the structure and function of apobec3g
|
US9101671B2
(en)
|
2007-01-03 |
2015-08-11 |
Sanford-Burnham Medical Research Institute |
Methods and compositions related to clot binding compounds
|
WO2008086002A2
(en)
|
2007-01-08 |
2008-07-17 |
Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services |
Slco1b3 genotype
|
US9896511B2
(en)
|
2007-01-10 |
2018-02-20 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies
|
WO2008121437A2
(en)
|
2007-02-08 |
2008-10-09 |
The Burnham Institute For Medical Research |
Trophinin-binding peptides and uses thereof
|
CA2687024A1
(en)
|
2007-05-09 |
2009-02-19 |
Burnham Institute For Medical Research |
Targeting host proteinases as a therapeutic strategy against viral and bacterial pathogens
|
AU2007353789B2
(en)
|
2007-05-23 |
2014-05-22 |
The Uab Research Foundation |
Detoxified pneumococcal neuraminidase and uses thereof
|
EP2617837A3
(en)
|
2007-06-08 |
2013-10-23 |
Biogen Idec MA Inc. |
Biomarkers for predicting anti-TNF responsiveness or non-responsiveness
|
US8999337B2
(en)
|
2007-06-11 |
2015-04-07 |
Abbvie Biotechnology Ltd. |
Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
|
PE20090368A1
(es)
|
2007-06-19 |
2009-04-28 |
Boehringer Ingelheim Int |
Anticuerpos anti-igf
|
PE20120259A1
(es)
|
2007-08-09 |
2012-04-04 |
Boehringer Ingelheim Int |
Anticuerpos anti-cd37
|
EP2268664B1
(en)
|
2007-12-03 |
2017-05-24 |
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services |
Doc1 compositions and methods for treating cancer
|
MX2010007728A
(es)
|
2008-01-15 |
2010-12-21 |
Abbott Gmbh & Co Kg |
Composiciones proteinicas en polvo y metodos para elaborar las mismas.
|
EP2119726B2
(en)
|
2008-05-14 |
2017-11-29 |
Immatics Biotechnologies GmbH |
Novel and powerful MHC-class II peptides derived from survivin and neurocan
|
US8946291B2
(en)
|
2008-08-15 |
2015-02-03 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Compositions and methods for treating pigmentary conditions and melanoma
|
US20120128684A1
(en)
|
2008-08-25 |
2012-05-24 |
Burnham Institute For Medical Research |
Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use
|
DK2172211T3
(en)
|
2008-10-01 |
2015-02-16 |
Immatics Biotechnologies Gmbh |
Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
|
WO2010065617A1
(en)
|
2008-12-02 |
2010-06-10 |
University Of Utah Research Foundation |
Pde1 as a target therapeutic in heart disease
|
MX2011006055A
(es)
|
2008-12-12 |
2011-07-04 |
Boehringer Ingelheim Int |
Anticuerpos anti-igf.
|
UY32341A
(es)
|
2008-12-19 |
2010-07-30 |
Glaxo Group Ltd |
Proteínas de unión antígeno novedosas
|
WO2011020107A2
(en)
|
2009-08-14 |
2011-02-17 |
Georgetown University |
Compositions and methods for detection and treatment of breast cancer
|
WO2011043980A1
(en)
|
2009-10-07 |
2011-04-14 |
Sanford Burnham Medical Research Institute |
Methods and compositions related to clot-binding lipid compounds
|
CN102612374A
(zh)
|
2009-11-12 |
2012-07-25 |
霍夫曼-拉罗奇有限公司 |
提升树突棘密度的方法
|
WO2011080050A2
(en)
|
2009-12-11 |
2011-07-07 |
Novartis Ag |
Binding molecules
|
US8912136B2
(en)
|
2009-12-18 |
2014-12-16 |
Sanford-Burnham Medical Research Institute |
Methods and compositions related to clot-binding compounds
|
AR079944A1
(es)
|
2010-01-20 |
2012-02-29 |
Boehringer Ingelheim Int |
Anticuerpo neutralizante de la actividad de un anticoagulante
|
WO2011094259A2
(en)
|
2010-01-28 |
2011-08-04 |
Glaxo Group Limited |
Cd127 binding proteins
|
US20110207789A1
(en)
|
2010-02-19 |
2011-08-25 |
Ye Fang |
Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
|
UA108227C2
(xx)
|
2010-03-03 |
2015-04-10 |
|
Антигензв'язуючий білок
|
GB201004551D0
(en)
|
2010-03-19 |
2010-05-05 |
Immatics Biotechnologies Gmbh |
NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
|
US20110293629A1
(en)
|
2010-05-14 |
2011-12-01 |
Bastid Jeremy |
Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists
|
AR081556A1
(es)
|
2010-06-03 |
2012-10-03 |
Glaxo Group Ltd |
Proteinas de union al antigeno humanizadas
|
PT2580240T
(pt)
|
2010-06-14 |
2019-03-29 |
Lykera Biomed S A |
Anticorpos as100a4 e utilizações terapêuticas dos mesmos
|
US8512295B2
(en)
|
2010-08-19 |
2013-08-20 |
West Pharmaceutical Services, Inc. |
Rigid needle shield
|
US9051619B2
(en)
|
2011-03-25 |
2015-06-09 |
Florida Agricultural and Mechanical University (FAMU) |
Methods and compositions for prostate cancer metastasis
|
MA34978B1
(fr)
|
2011-03-30 |
2014-03-01 |
Boehringer Ingelheim Int |
Antidotes pour anticoagulants
|
PL221015B1
(pl)
*
|
2011-04-11 |
2016-02-29 |
Akademia Medyczna Im Piastów Śląskich |
Sposób otrzymywania inhibitorów cysteinowych peptydaz o czystości elektroforetycznej z materiałów biologicznych
|
EP2702077A2
(en)
|
2011-04-27 |
2014-03-05 |
AbbVie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
KR20140104344A
(ko)
|
2011-05-20 |
2014-08-28 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 시크리터리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비시스 |
T 세포 매개성 질병의 병증을 개선하기 위한 tl1a-dr3의 상호작용의 차단 및 그것의 항체
|
WO2013003680A1
(en)
|
2011-06-30 |
2013-01-03 |
Genentech, Inc. |
Anti-c-met antibody formulations
|
EP2761298B1
(en)
|
2011-09-30 |
2017-10-25 |
Sarcotein Diagnostics, LLC |
Bin1 expression as a marker of cancer
|
US20130122005A1
(en)
|
2011-10-27 |
2013-05-16 |
Paul Adam |
Anticancer combination therapy
|
WO2013088240A1
(en)
|
2011-12-13 |
2013-06-20 |
Sony Corporation |
Memory device
|
US9150645B2
(en)
|
2012-04-20 |
2015-10-06 |
Abbvie, Inc. |
Cell culture methods to reduce acidic species
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
EP2878670B1
(en)
|
2012-06-08 |
2019-08-07 |
Kinki University |
Antibody against transporter and use thereof
|
EP2870238A4
(en)
|
2012-07-05 |
2016-03-09 |
Ohio State Innovation Foundation |
COMPOSITIONS AND METHODS ASSOCIATED WITH VIRAL VACCINES
|
KR20150043523A
(ko)
|
2012-09-02 |
2015-04-22 |
애브비 인코포레이티드 |
단백질 불균일성의 제어 방법
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
US20140094383A1
(en)
|
2012-10-02 |
2014-04-03 |
Ohio State Innovation Foundation |
Tethered Lipoplex nanoparticle Biochips And Methods Of Use
|
MX367136B
(es)
|
2012-10-18 |
2019-08-06 |
Inosan Biopharma S A Star |
Proceso para purificar fragmentos de anticuerpos polivalentes derivados de plasma hiperinmune.
|
US10407503B2
(en)
|
2012-11-30 |
2019-09-10 |
The Regents Of The University Of California |
Fully human antibodies and fragments recognizing human c-Met
|
US20140255413A1
(en)
|
2013-03-07 |
2014-09-11 |
Boehringer Ingelheim International Gmbh |
Combination therapy for neoplasia treatment
|
EP2830651A4
(en)
|
2013-03-12 |
2015-09-02 |
Abbvie Inc |
HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
WO2014159579A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
US9783576B2
(en)
|
2013-06-11 |
2017-10-10 |
Sanford-Burnham Medical Research Institute |
Compositions and methods for targeted endometriosis treatment
|
TWI776192B
(zh)
|
2013-08-05 |
2022-09-01 |
德商伊瑪提克斯生物科技有限公司 |
新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物(四)
|
US9598667B2
(en)
|
2013-10-04 |
2017-03-21 |
Abbvie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
GB201319446D0
(en)
|
2013-11-04 |
2013-12-18 |
Immatics Biotechnologies Gmbh |
Personalized immunotherapy against several neuronal and brain tumors
|
US10203327B2
(en)
|
2013-11-05 |
2019-02-12 |
Novartis Ag |
Organic compounds
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
BR112016021383A2
(pt)
|
2014-03-24 |
2017-10-03 |
Genentech Inc |
Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
|
EP3502698A1
(en)
|
2014-05-05 |
2019-06-26 |
MicroBPlex, Inc. |
Media elaborated with newly synthesized antibodies and uses thereof
|
GB201408255D0
(en)
|
2014-05-09 |
2014-06-25 |
Immatics Biotechnologies Gmbh |
Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
|
GB201411037D0
(en)
|
2014-06-20 |
2014-08-06 |
Immatics Biotechnologies Gmbh |
Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
GB201501017D0
(en)
|
2014-12-23 |
2015-03-04 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
|
WO2016141088A1
(en)
|
2015-03-02 |
2016-09-09 |
Sarcotein Diagnostics, Llc |
13+/17+ bin1 expression as a marker of cardiac disorders
|
GB201505585D0
(en)
|
2015-03-31 |
2015-05-13 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
|
GB201507030D0
(en)
|
2015-04-24 |
2015-06-10 |
Immatics Biotechnologies Gmbh |
Immunotherapy against lung cancers, in particular NSCLC
|
GB201507719D0
(en)
|
2015-05-06 |
2015-06-17 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
|
EP3919507A3
(en)
|
2015-07-01 |
2022-01-12 |
Immatics Biotechnologies GmbH |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
GB201511546D0
(en)
|
2015-07-01 |
2015-08-12 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
MA51531A
(fr)
|
2015-07-06 |
2020-11-11 |
Immatics Biotechnologies Gmbh |
Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l' oesophage et d'autres cancers
|
GB201513921D0
(en)
|
2015-08-05 |
2015-09-23 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
|
GB201522667D0
(en)
|
2015-12-22 |
2016-02-03 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
|
GB201602918D0
(en)
|
2016-02-19 |
2016-04-06 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
|
CN116375797A
(zh)
|
2016-03-01 |
2023-07-04 |
伊玛提克斯生物技术有限公司 |
用于膀胱癌和其他癌症免疫治疗的肽、肽组合物和细胞类药物
|
CN109071605A
(zh)
|
2016-04-06 |
2018-12-21 |
伊玛提克斯生物技术有限公司 |
用于aml和其他癌症免疫治疗的新型肽和肽组合物
|
AR108516A1
(es)
|
2016-05-18 |
2018-08-29 |
Boehringer Ingelheim Int |
Moléculas de anticuerpo anti-pd1 y anti-lag3 para el tratamiento del cáncer
|
TWI796299B
(zh)
|
2016-08-26 |
2023-03-21 |
德商英麥提克生物技術股份有限公司 |
用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
|
EP3523416A4
(en)
|
2016-10-05 |
2020-04-15 |
University of Central Florida Research Foundation, Inc. |
METHODS AND COMPOSITIONS ASSOCIATED WITH ANTI-CANCER THERAPIES OF NK AND ANTI-PDL1 CELLS
|
EP3360898A1
(en)
|
2017-02-14 |
2018-08-15 |
Boehringer Ingelheim International GmbH |
Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
|
EP3559037A1
(en)
|
2016-12-22 |
2019-10-30 |
Wake Forest University Health Sciences |
Sirp-gamma targeted agents for use in the treatment of cancer
|
WO2018138257A1
(en)
|
2017-01-27 |
2018-08-02 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
|
GB201701404D0
(en)
|
2017-01-27 |
2017-03-15 |
Micropharm Ltd |
Therapies for treating inflammatory disorders
|
US11427645B2
(en)
|
2017-03-15 |
2022-08-30 |
Oxford Biomedica (Uk) Limited |
5T4-targeting agents and methods
|
EP3600419B1
(en)
|
2017-03-20 |
2023-08-09 |
Vaccinex, Inc. |
Treatment of cancer with a semaphorin-4d antibody in combination with an epigenetic modulating agent
|
KR102653567B1
(ko)
|
2017-03-28 |
2024-04-02 |
오하이오 스테이트 이노베이션 파운데이션 |
인간 pd1 펩티드 백신 및 이의 용도
|
EP3385699A1
(en)
|
2017-04-07 |
2018-10-10 |
Universitat Rovira i Virgili |
Optofluidic device and method for detecting circulating tumour cells
|
WO2018189148A1
(en)
|
2017-04-10 |
2018-10-18 |
Immatics Biotechnologies Gmbh |
Peptides and combination thereof for use in the immunotherapy against cancers
|
WO2018189152A2
(en)
|
2017-04-10 |
2018-10-18 |
Immatics Biotechnologies Gmbh |
Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
|
SG11201909153UA
(en)
|
2017-04-10 |
2019-10-30 |
Immatics Biotechnologies Gmbh |
Peptides and combination thereof for use in the immunotherapy against cancers
|
US10800823B2
(en)
|
2017-07-07 |
2020-10-13 |
Immatics Biotechnologies Gmbh |
Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
|
SG11201913302SA
(en)
|
2017-07-07 |
2020-01-30 |
Immatics Biotechnologies Gmbh |
Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers
|
CA3068203A1
(en)
|
2017-07-14 |
2019-01-17 |
The Francis Crick Institute Limited |
Analysis of hla alleles in tumours and the uses thereof
|
WO2019070108A1
(es)
|
2017-10-02 |
2019-04-11 |
Laboratorios Silanes S.A. De C.V. |
Proceso de alto rendimiento para la producción de antivenenos de fragmentos f (ab') 2 de anticuerpos
|
DE102018107224A1
(de)
|
2018-02-21 |
2019-08-22 |
Immatics Biotechnologies Gmbh |
Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
TW202016131A
(zh)
|
2018-05-16 |
2020-05-01 |
德商英麥提克生物技術股份有限公司 |
用於抗癌免疫治療的肽
|
EP3569618A1
(en)
|
2018-05-19 |
2019-11-20 |
Boehringer Ingelheim International GmbH |
Antagonizing cd73 antibody
|
EP3802616A4
(en)
|
2018-06-04 |
2022-03-30 |
University of Maryland, Baltimore |
METHODS OF PREVENTING ACUTE KIDNEY DAMAGE
|
US10925947B2
(en)
|
2018-06-29 |
2021-02-23 |
Immatics Biotechnologies Gmbh |
A*03 restricted peptides for use in immunotherapy against cancers and related methods
|
WO2020006493A1
(en)
|
2018-06-29 |
2020-01-02 |
North Carolina State University |
In situ sprayed bioresponsive immunotherapeutic gel for post-surgical treatment
|
TW202019955A
(zh)
|
2018-07-31 |
2020-06-01 |
德商英麥提克生物技術股份有限公司 |
B*07 限制肽和肽組合的抗癌免疫治療和相關方法
|
US11945850B2
(en)
|
2018-09-17 |
2024-04-02 |
Immatics Biotechnologies Gmbh |
B*44 restricted peptides for use in immunotherapy against cancers and related methods
|
TW202024121A
(zh)
|
2018-09-18 |
2020-07-01 |
德商英麥提克生物技術股份有限公司 |
A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
|
GB201818477D0
(en)
|
2018-11-13 |
2018-12-26 |
Emstopa Ltd |
Tissue plasminogen activator antibodies and method of use thereof
|
WO2020115223A1
(en)
|
2018-12-05 |
2020-06-11 |
Katholieke Universiteit Leuven |
S100a4 as a marker of treatment with spironolactone, pioglitazone and metformin
|
TW202039535A
(zh)
|
2018-12-18 |
2020-11-01 |
德商英麥提克生物技術股份有限公司 |
B*08限制肽和肽組合物抗癌免疫治療和相關方法
|
WO2020225549A1
(en)
|
2019-05-06 |
2020-11-12 |
The Francis Crick Institute Limited |
Method for preventing inflammation
|
MX2021015970A
(es)
|
2019-06-21 |
2022-04-06 |
Vaccinex Inc |
Terapia de combinacion con bloqueo de semaforina-4d (sema4d) y terapia de dc1.
|
MX2022003195A
(es)
|
2019-09-18 |
2022-04-11 |
Molecular Templates Inc |
Moleculas de union a pd-l1 que comprenden andamios de la subunidad a de la toxina shiga.
|
US11918649B2
(en)
|
2019-09-18 |
2024-03-05 |
Molecular Templates, Inc. |
PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds
|
TW202128756A
(zh)
|
2019-10-02 |
2021-08-01 |
德商百靈佳殷格翰國際股份有限公司 |
用於癌症治療之多重專一性結合蛋白
|
EP4146327A1
(en)
|
2020-05-08 |
2023-03-15 |
Novocure GmbH |
Compositions and methods of applying alternating electric fields to pluripotent stem cells
|
BR112022021447A2
(pt)
|
2020-05-19 |
2022-12-13 |
Boehringer Ingelheim Int |
Moléculas de ligação para o tratamento de câncer
|
TW202229312A
(zh)
|
2020-09-29 |
2022-08-01 |
德商英麥提克生物技術股份有限公司 |
由非hla-a*02顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
|
DE102020125465A1
(de)
|
2020-09-29 |
2022-03-31 |
Immatics Biotechnologies Gmbh |
Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
DE102020125457A1
(de)
|
2020-09-29 |
2022-03-31 |
Immatics Biotechnologies Gmbh |
Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
|
US20220119536A1
(en)
|
2020-10-21 |
2022-04-21 |
Boehringer Ingelheim International Gmbh |
Agonistic trkb binding molecules for the treatment of eye diseases
|
TW202241925A
(zh)
|
2021-01-15 |
2022-11-01 |
德商英麥提克生物技術股份有限公司 |
用於不同類型癌症免疫治療的hla展示肽
|
AR126161A1
(es)
|
2021-06-17 |
2023-09-27 |
Boehringer Lngelheim Int Gmbh |
Moléculas de fijación triespecíficas novedosas
|
WO2023089131A1
(en)
|
2021-11-19 |
2023-05-25 |
Lykera Biomed, S.A. |
Treatment and diagnosis of diseases associated to pathogenic fibrosis
|
CN114132883B
(zh)
*
|
2021-11-29 |
2023-12-22 |
义乌市奥飞创意设计有限公司 |
一种可降低气溶胶污染的血清蛋白抑制剂注射装载设备
|
WO2024013315A1
(en)
|
2022-07-15 |
2024-01-18 |
Boehringer Ingelheim International Gmbh |
Binding molecules for the treatment of cancer
|